Drug Search Results
More Filters [+]

Gendicine

Alternative Names: gendicine, rad-p53, radp53, rad p53, radp-53, radp 53
Latest Update: 2024-04-18
Latest Update Note: PubMed Publication

Product Description

Gendicine (recombinant human p53 adenovirus), developed by Shenzhen SiBiono GeneTech Co. Ltd., was approved in 2003 by the China Food and Drug Administration (CFDA) as a first-in-class gene therapy product to treat head and neck cancer, and entered the commercial market in 2004. Gendicine is a biological therapy that is delivered via minimally invasive intratumoral injection, as well as by intracavity or intravascular infusion. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/29338444/)

Mechanisms of Action: Gene Therapy,p53

Novel Mechanism: Yes

Modality: Gene Therapy

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Shenzhen SiBiono GeneTech
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Gendicine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Oncology Solid Tumor Unspecified

Phase 2: Head and Neck Cancer|Hepatocellular Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ChiCTR2100052227

N/A

Not yet recruiting

Nasopharyngeal Cancer

2024-01-01

rAd-p53-J1002

P2

Unknown status

Head and Neck Cancer

2018-12-01

rAd-p53-H14006

P2

Unknown status

Hepatocellular Carcinoma

2017-05-01

rAd-p53-003

P4

Unknown status

Oncology Solid Tumor Unspecified

2012-08-01

Recent News Events